Prospective evaluation of biomarkers for prediction of quality of life in community-acquired pneumonia

Nickler, Manuela; Schaffner, Daniela; Ottiger, Manuel; Thomann, Robert V.; Hoess, Claus; Henzen, Christoph; Müeller, Beat; Schuetz, Philipp

doi:10.1515/cclm-2016-0001

Cited by 15 publications

(13 citation statements)

References 67 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…The ESC guidelines state that NPs should be considered in patients with pulmonary embolism . While the use in pneumonia has not been evaluated in other guidelines, we think that the use of NPs in this indication might allow the early detection of previously undiagnosed or underestimated cardiac disease possibly amendable to therapeutic interventions in a relevant proportion of patients with pneumonia and therefore hopefully ameliorate the substantial mortality observed in pneumonia and substantially elevated NPs . By contrast, low NPs can rule out any relevant cardiac dysfunction.…”

Section: Risk Stratification Of Pulmonary Embolism and Pneumoniamentioning

confidence: 99%

Heart Failure Association of the European Society of Cardiology practical guidance on the use of natriuretic peptide concentrations

Müeller

McDonald

Boer

et al. 2019

European J of Heart Fail

564

473

View full text Add to dashboard Cite

Natriuretic peptide [NP; B-type NP (BNP), N-terminal proBNP (NT-proBNP), and midregional proANP (MR-proANP)] concentrations are quantitative plasma biomarkers for the presence and severity of haemodynamic cardiac stress and heart failure (HF). End-diastolic wall stress, intracardiac filling pressures, and intracardiac volumes seem to be the dominant triggers. This paper details the most important indications for NPs and highlights 11 key principles underlying their clinical use shown below.(i) NPs should always be used in conjunction with all other clinical information.(ii) NPs are reasonable surrogates for intracardiac volumes and filling pressures. (iii) NPs should be measured in all patients presenting with symptoms suggestive of HF such as dyspnoea and/or fatigue, as their use facilitates the early diagnosis and risk stratification of HF. (iv) NPs have very high diagnostic accuracy in discriminating HF from other causes of dyspnoea: the higher the NP, the higher the likelihood that dyspnoea is caused by HF. (v) Optimal NP cut-off concentrations for the diagnosis of acute HF (very high filling pressures) in patients presenting to the emergency department with acute dyspnoea are higher compared with those used in the diagnosis of chronic HF in patients with dyspnoea on exertion (mild increase in filling pressures at rest). (vi) Obese patients have lower NP concentrations, mandating the use of lower cut-off concentrations (about 50% lower). (vii) In stable HF patients, but also in patients with other cardiac disorders such as myocardial infarction, valvular heart disease, atrial fibrillation or pulmonary embolism, NP concentrations have high prognostic accuracy for death and HF hospitalization.

show abstract

Section: Risk Stratification Of Pulmonary Embolism and Pneumoniamentioning

confidence: 99%

Heart Failure Association of the European Society of Cardiology practical guidance on the use of natriuretic peptide concentrations

Müeller

McDonald

Boer

et al. 2019

European J of Heart Fail

564

473

View full text Add to dashboard Cite

show abstract

“…Upon admission to the ICU, blood samples from each patient were drawn for routine chemistry measurements and additionally, serum samples were aliquoted and frozen at −80 • C until retesting for the measurement of metabolomics biomarkers [23][24][25][26]. As secondary tubes, conical false bottom tubes made of polyethylene with a lamellar plug were used.…”

Section: Methodsmentioning

confidence: 99%

Low Plasma Sphingomyelin Levels Show a Weak Association with Poor Neurological Outcome in Cardiac Arrest Patients: Results from the Prospective, Observational COMMUNICATE Trial

Boerlin

Luescher

Becker

et al. 2020

JCM

Self Cite

View full text Add to dashboard Cite

There is interest in novel blood markers to improve risk stratification in patients presenting with cardiac arrest. We assessed associations of different plasma sphingomyelin concentrations and neurological outcome in patients with cardiac arrest. In this prospective observational study, adult patients with cardiac arrest were included upon admission to the intensive care unit (ICU). We studied associations of admission plasma levels of 15 different sphingomyelin species with neurological outcome at hospital discharge (primary endpoint) defined by the modified Rankin Scale by the calculation of univariable and multivariable logistic regression models adjusted for age, gender, and clinical shock markers. We included 290 patients (72% males, median age 65 years) with 162 (56%) having poor neurological outcome at hospital discharge. The three sphingomyelin species SM C24:0, SM(OH) C22:1, and SM(OH) C24:1 were significantly lower in patients with poor neurological outcome compared to patients with favorable outcome with areas under the curve (AUC) of 0.58, 0.59, and 0.59. SM(OH) C24:1 was independently associated with poor neurological outcome in a fully-adjusted regression model (adjusted odds ratio per log-transformed unit increase in SM(OH) C24:1 blood level 0.18, 95% CI 0.04 to 0.87, p = 0.033). Results were similar for 1-year mortality. Low admission sphingomyelin levels showed a weak association with poor neurological outcome in patients after cardiac arrest. If validated in future studies, a better understanding of biological sphingomyelin function during cardiac arrest may help to further advance the therapeutic approach and risk stratification in this vulnerable patient group.

show abstract

“…While most studies focused on short-term (i.e. 30 days) outcomes, some studies also looked at long-term outcomes including mortality, quality of life, among others [18,19]. The search for accurate prognostic markers has been supported by novel approaches including metabolomics.…”

Section: Prognostic Biomarkers For Risk Stratificationmentioning

confidence: 99%

Prospective evaluation of biomarkers for prediction of quality of life in community-acquired pneumonia

Cited by 15 publications

References 67 publications

Heart Failure Association of the European Society of Cardiology practical guidance on the use of natriuretic peptide concentrations

Heart Failure Association of the European Society of Cardiology practical guidance on the use of natriuretic peptide concentrations

Low Plasma Sphingomyelin Levels Show a Weak Association with Poor Neurological Outcome in Cardiac Arrest Patients: Results from the Prospective, Observational COMMUNICATE Trial

Personalized medicine of patients with respiratory infections through the measurement of specific blood biomarkers: fact or fiction?

Contact Info

Product

Resources

About